Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for serious diseases. Founded in 2015, Matinas has made significant strides in the biotechnology sector, particularly in the areas of lipid-based drug delivery systems and oral formulations. The company’s flagship product, MAT2203, is a unique oral formulation of amphotericin B, designed to treat fungal infections with improved safety and efficacy. Matinas BioPharma's commitment to advancing drug delivery technologies positions it as a notable player in the biopharma industry, with a strong emphasis on enhancing patient outcomes. With a robust pipeline and strategic partnerships, Matinas continues to solidify its market position and drive innovation in the healthcare landscape.
DitchCarbon Score
How does Matinas BioPharma Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Matinas BioPharma Holdings, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Matinas BioPharma Holdings, Inc.'s reported carbon emissions
Matinas BioPharma Holdings, Inc., headquartered in the US, currently does not have available data on carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. In the absence of concrete emissions data, it is essential to note that many companies in the biopharmaceutical sector are increasingly focusing on sustainability and climate commitments. This trend often includes setting science-based targets for emissions reductions and implementing initiatives to minimise their carbon footprint. As Matinas BioPharma continues to operate within this evolving industry context, future disclosures regarding their climate commitments and emissions data may provide further insights into their environmental impact and sustainability efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Matinas BioPharma Holdings, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
